Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.
October 2025
FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.
Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.
Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.
Explore the profound connection between emotions and oncology pharmacy, highlighting the importance of acknowledging feelings in patient care.
Explore how targeted therapies and immunotherapies transform oncology, highlighting novel antibody treatments and their impact on patient care and outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
2
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
3
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
4
Bridging Response Emerges as Key Predictor of Cilta-Cel Outcomes in CARTITUDE-4
5
